Avastin fails to hit colon cancer target
SAN FRANCISCO, April 22 (UPI) -- The drug Avastin fell short in a clinical trial of its goal to reduce the recurrence of early-stage colon cancer, U.S. drug maker Genentech says.

| Stories | Photos | People | Comments |
View Caption